Company / Capital Expenditures
Arcadia Biosciences, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$16.0K
FY2025
5-year range
$5.0K / $2.3M
FY2021-FY2025
Trend
+220.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +220% YoY in FY2025, a notable deviation from the 9-year average annual change of +81%.
Based on SEC 10-K filings.
$16,000 in FY2025 with a 5-year CAGR of -59.5%.
Declined from $72,000 to $16,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -74.9%
- 5-Year CAGR
- -59.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -59.5%, indicating a declining trend.
- In FY2025, capital expenditures increased 220.0% year-over-year.
- Peak capital expenditures was recorded in FY2021.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.0K | +220.0% |
| FY2024 | $5.0K | -93.1% |
| FY2023 | $72.0K | -92.9% |
| FY2022 | $1.0M | -56.9% |
| FY2021 | $2.3M | +58.1% |
| FY2020 | $1.5M | +490.8% |
| FY2019 | $250.0K | +216.5% |
| FY2018 | $79.0K | -65.8% |
| FY2017 | $231.0K | +53.0% |
| FY2016 | $151.0K | +2.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026